External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents

Journal of Infectious Diseases

Volumn 203, Issue 1, 2011, Pages 58-65

  Vardas, Eftyhia ^a,b   Giuliano, Anna R ^c   Goldstone, Stephen ^d   Palefsky, Joel M ^e   Moreira Jr , Edson D ^f   Penny, Mary E ^g   Aranda, Carlos ^h   Jessen, Heiko ⁱ   Moi, Harald ^j   Ferris, Daron G ^k   Liaw, Kai Li ^l   Marshall, J Brooke ^l   Vuocolo, Scott ^l   Barr, Eliav ^l   Haupt, Richard M ^l   Garner, Elizabeth I O ^l   Guris, Dalya ^l  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b LANCET LABORATORIES   (South Africa)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g INSTITUTO DE INVESTIGACIÓN NUTRICIONAL   (Peru)

^h INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

ⁱ J2: Private Clinic for Infectious Diseases   (Germany)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k MEDICAL COLLEGE OF GEORGIA   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AFRICA; ANUS; ARTICLE; CIRCUMCISION; CONDOM; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DISEASE ASSOCIATION; HETEROSEXUAL MALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PENIS; PERINEUM; PREVALENCE; PRIORITY JOURNAL; SCROTUM; SEXUALITY; VIRUS DETECTION; WART VIRUS;

ADOLESCENT; ADULT; ANAL CANAL; ANTIBODIES, VIRAL; DNA, VIRAL; GENITAL DISEASES, MALE; HETEROSEXUALITY; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENIS; PERINEUM; PREVALENCE; RISK FACTORS; SCROTUM; YOUNG ADULT;

EID: 79851472653     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq015     Document Type: Article

References (31)

1. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008; 26(Suppl 10):K17-28.
2. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24(Suppl 3):S11-25.
3. Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346:1105-12. (Pubitemid 34984600)
4. Shah KV. Human papillomaviruses and anogenital cancers. N Engl J Med 1997; 337:1386-8. (Pubitemid 27467776)
5. Zunzunegui MV, King MC, Coria CF, Charlet J. Male influences on cervical cancer risk. Am J Epidemiol 1986; 123:302-7. (Pubitemid 16158552)
6. Giuliano A, Palefsky J, Goldstone SE, et al. Quadrivalent HPV vaccine efficacy against HPV 6/11/16/18 infection and disease in men. New Engl J Med 2010. In press.
7. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002; 89:285-93. (Pubitemid 35351547)
8. Shepherd J, Weston R, Peersman G, Napuli IZ. Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer. Cochrane Database Syst Rev 2000: CD001035.
9. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomark Prev 2008; 17:2036-43.
10. Giuliano AR, Lazcano E, Villa LL, et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer 2009; 124:1251-7.
11. Lajous M, Mueller N, Cruz-Valdéz A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomark Prev 2005; 14:1710-6. (Pubitemid 40995084)
12. Wikström A, Popesca C, Forslund O. Asymptomatic penile HPV infection: a prospective study. Int J STD AIDS 2000; 11:80-4. (Pubitemid 30081609)
13. Hippeläinen M, Syrjänen S, Hippeläinen M, et al. Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis 1993; 20:321-8. (Pubitemid 23347227)
14. van Doornum GJJ, Hooykaas C, Juffermans LHJ, et al. Prevalence of human papillomavirus infections among heterosexual men and women with multiple sexual partners. J Med Virol 1992; 37: 13-21.
15. Kjaer SK, Munk C, Winther JF, Jørgensen HO, Meijer CJ, van den Brule AJ. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomark Prev 2005; 14:1528-33. (Pubitemid 40807357)
16. Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198:827-35.
17. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis 2007; 196:1128-36. (Pubitemid 47580267)
18. Palefsky JM. Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst Monogr 1998; 23:15-20.
19. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183:383-91. (Pubitemid 32105597)
20. Lu B, Wu Y, Nielson CM, et al. Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis 2009; 199:362-71.
21. Nielson CM, Harris RB, Dunne EF, et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis 2007; 196:1137-45. (Pubitemid 47580268)
22. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26:6844-51.
23. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
24. Iftner T, Germ L, Swoyer R, et al. Study comparing human papillomavirus (HPV) real-timemultiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays. J Clin Microbiol 2009; 47:2106-13.
25. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
26. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomavirus 6, 11, 16 and 18. Clin Diagn Lab Immunol 2005; 12:959-69.
27. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
28. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360:1298-309.
29. Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis 2008; 197:1676-84. (Pubitemid 351919631)
30. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
31. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-56.